- Barrons.com•6 hours ago
Remember when Bristol-Myers Squibb (BMY) was getting hit so hard that everyone was wondering whether it would find itself acquired by another pharmaceutical, with Pfizer (PFE), Novartis (NVS), Gilead Sciences (GILD), and Roche mentioned as possible buyers? In a note released yesterday, Credit Suisse analyst Vamil Divan and team revisit the possibility of Pfizer taking over Bristol-Myers with their colleagues at the firm's HOLT team...and find that it just might provide "an opportunity for value creation" after all.
- American City Business Journals•7 hours ago
Akcea Therapeutics, a Cambridge-based subsidiary of Ionis Pharmaceuticals developing treatments for lipid disorders, said Monday that it plans to raise up to $100 million in an initial public offering. The 26-employee company said in a federal filing that it had applied to list its stock on the Nasdaq under the symbol “AKCA.” It would be the second Massachusetts-based biotech to go public so far in 2017, after Cambridge cancer drug developer Jounce Therapeutics (JNCE). A $100 million IPO would also be one of the largest offerings for a local biotech in recent memory.
- Motley Fool•7 hours ago
No tending needed for big pharma stocks Johnson & Johnson, Pfizer, and Novartis.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||74.78 - 75.32|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||26.82|
|Dividend & Yield||2.75 (3.69%)|
|1y Target Est||N/A|